scholarly journals [Corrigendum] STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway

2020 ◽  
Vol 45 (1) ◽  
pp. 401-402
Author(s):  
Wenpeng Jiang ◽  
Shiting Huang ◽  
Liang Song ◽  
Zhou Wang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Pi3k Pathway ◽  
Prognostic Predictor

scholarly journals The Postoperative Lymphocyte to Monocyte Ratio Change Predicts Poor Clinical Outcome in Patients with Esophageal Squamous Cell Carcinoma Undergoing Curative Resection

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Qian Song ◽  
Jun-zhou Wu ◽  
Hui-fen Jiang ◽  
Sheng Wang ◽  
Shu-nv Cai
Keyword(s):  
Squamous Cell Carcinoma ◽  
Clinical Outcome ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Dynamic Change ◽  
Disease Free Survival ◽  
Prognostic Predictor ◽  
Lymphocyte To Monocyte Ratio ◽  
Curative Operation

Background. Postoperative lymphocyte to monocyte ratio (post-LMR) change (LMRc) reflects the dynamic change of balance between inflammatory reaction and immune reaction after curative operation. An elevated preoperative LMR (pre-LMR) has been shown to be a prognostic factor in patients with esophageal squamous cell carcinoma (ESCC), but the clinical value of the LMRc remains unknown. Methods. 674 patients in ESCC undergoing curative operation were enrolled in this study. LMRc (LMRc=pre‐LMR–post‐LMR) was counted on the basis of data within one week before and after operation. The median of LMRc was chosen to be the optimal cut-off value to evaluate the prognostic value of LMRc. Results. Kaplan-Meier curves revealed that LMRc≤1.59 was significantly associated with worse overall survival (OS) (P=0.003) and disease-free survival (DFS) (P=0.008). Multivariate analysis suggested that LMRc could serve as an independent prognostic predictor for both OS (P=0.006, HR=0.687, 95% CI 0.526-0.898) and DFS (P=0.003, HR=0.640, 95% CI 0.476-0.859). Conclusions. LMRc is a promising prognostic predictor for predicting the worse clinical outcome in patients with ESCC undergoing curative operation.

Identification of clinically actionable mutations and immunotherapy biomarkers in Chinese esophageal squamous cell carcinoma patients.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15576-e15576
Author(s):  
Minghui Wang ◽  
Junkai Zhang ◽  
Weiquan Gu ◽  
Yun Li ◽  
RongFeng Song ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Pi3k Pathway ◽  
Genomic Alteration ◽  
Cancer Genes ◽  
Ffpe Tumor ◽  
Tumor Mutational Burden ◽  
Next Generation Sequencing Ngs

e15576 Background: Esophageal squamous cell carcinoma (ESCC), the major esophageal cancer histological type in East Asia, has limited therapeutic options and is associated with poor prognosis. Here, we identified clinically actionable genomic alteration (GA) for potential targeted and immunotherapy in Chinese ESCC patients by next generation sequencing (NGS). Methods: Clinical data were collected from 150 ESCC patients from March 2011 to December 2018, with a median follow-up of 34 months. NGS-panel sequencing of 466 cancer genes was performed on FFPE tumor and matched blood sample. Tumor mutational burden (TMB) was assessed in all patients by standard NGS algorithms. PD-L1 expression was evaluated in 61 samples by IHC (28-8 Ab). Results: Overall, 75.5% of ESCC patients harbored at least one clinically actionable GAs with the most frequent being CCND1 (40%), CDKN2A (40%), CDKN2B (24%), PIK3CA (14%) and FGFR1 (8%). Most clinically actionable GAs occurred in genes involved with cell cycle (61%) and with PI3K pathway (23%). Clinically actionable GAs also distributed in BRCA2 (5%), ATM (3%), MET amp (3%), KIT (3%), EGFR mut (2%), PDGFRA (2%) and ERBB2 amp (1%). The lowest 25% (TMB-L), median and highest 25% TMB (TMB-H) value was 4.6, 6.9 and 9.2 muts/Mb, respectively. Compared with younger patients, patients ≥50 years had higher TMB ( p= 0.047). Compared with TMB-L ESCCs, frequencies of NOTCH2 (15.9% vs 0%, p= 0.015), PIK3CA (22.7% vs 2.8%, p= 0.019) and KMT2D (25.0% vs 5.6%, p= 0.031) were significantly higher in TMB-H. Notably, amplification in 11q13 region, MDM2/ MDM4 and EGFR, which potentially relates to immunotherapy hyperprogression, accounted for 48% of TMB-H. Eleven patients (18%) showed PD-L1≥1%, in which 7 pts were also TMB-H. Conclusions: In Chinese ESCCs, clinically actionable GAs were detected in most patients, which highlights the promise of molecularly directed therapies. Patients with PD-L1 positive/TMB-H/both, who could potentially benefit from immunotherapy, accounted for 41%. Older age, NOTCH2, PIK3CA and KMT2D mutations correlated with TMB-H.

Progress of Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma

2012 ◽  
Vol 63 (2) ◽  
pp. 195-195
Author(s):  
K. Minashi ◽  
T. Yano ◽  
T. Kojima ◽  
M. Onozawa ◽  
K. Nihei ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Resectable Esophageal
Sign in / Sign up

Export Citation Format

Share Document